Momentis Surgical, a company focused on developing minimally invasive surgical robotic systems, has announced FDA 510(k) clearance for its second-generation Anovo Robotic Platform. This clearance follows a previous approval in October for the first-generation Anovo system, marking a significant advancement in the field of robotic surgery.
The second-generation Anovo platform incorporates several upgrades based on clinical insights. A key feature is its FDA clearance for use in both forward and backward flexion positions, whether single or multiple incisions are used. This capability provides surgeons with unprecedented access and maneuverability during procedures. The system also includes enhanced ergonomic capabilities with sensory feedback, designed to provide surgeons with intuitive control of the robotic arms. Furthermore, a video layer with annotation capabilities aims to improve communication and collaboration among the surgical team in the operating room.
The Anovo system's design incorporates robotic arms that mimic human arms, offering fine motor skills with 360-degree rotation joints and flexibility across multiple planes. This allows surgeons to navigate complex anatomical structures and avoid obstacles while maintaining optimal working angles. Multiple instruments can be inserted through a single incision, potentially reducing patient trauma and improving recovery times.
According to Dvir Cohen, CEO of Momentis Surgical, this FDA approval represents a significant milestone in the company's plan to advance robotic surgery. The company intends to expand its global presence, with plans to introduce Anovo to European and Asian markets in the near future.
Eyal Lifshitz, Managing Partner of Peregrine Ventures, highlighted the potential of the Anovo system to broaden access to robotic surgery. Its compact size and user-friendliness could enable its use in a wider range of medical institutions, including outpatient surgical centers.
